ClinicalTrials.gov
ClinicalTrials.gov Menu

Randomized Trial of Low-dose Naproxen in Cognitively Intact Persons at Risk of Alzheimer's Dementia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02702817
Recruitment Status : Completed
First Posted : March 9, 2016
Last Update Posted : August 1, 2017
Sponsor:
Collaborators:
McGill University
Johns Hopkins University
Information provided by (Responsible Party):
John C. S. Breitner, Douglas Mental Health University Institute

Brief Summary:
Two-year double-masked trial of over-the-counter dosage of naproxen sodium vs placebo in 200 cognitively normal participants with a parental or multiplex first-degree family history Alzheimer's disease (AD) dementia. Primary outcomes are decline in cognitive function and slope of change in a summary Alzheimer Progression Score derived from serial assessment of neuroimaging, biochemical, and sensori-neural biomarker indicators of pre-clinical disease -- all believed likely to reflect progress of preclinical AD in this high risk cohort. Approximately 2/3 of participants have volunteered also for serial lumbar punctures for analysis of cerebrospinal fluid. A two-year off-treatment delayed-washout phase is planned to examine sustained treatment effects and evidence of disease modification.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Cognitive Decline Due to Alzheimer Disease Mild Cognitive Impairment Due to Alzheimer Disease Drug: Naproxen Drug: Placebo Phase 2

Detailed Description:
The trial enrolled 195 cognitively normal persons aged 60+ with either a parental history of AD or a history of two or more affected first-degree relatives. Persons aged 55-59 were admitted if their current age was <= 15 years younger than AD onset in their index relative. Such persons are believed to be at approximately 3-fold increased risk of AD dementia. We expected a majority of them to show evidence of progressive pre-clinical AD. Participants were randomized 1:1 to receive the common non-steroidal anti-inflammatory drug (NSAID) naproxen in over-the-counter dosage (naproxen sodium 220 mg) or identical-appearing placebo tablets twice daily. At baseline and at three follow-up visits (3 months, 12 months and 24 months after randomization) they were tested for cognitive abilities and undergo brain imaging with both structural and functional MRI. They are also tested for sensori-neural capacities in olfactory identification and in the ability to discern spoken language in a distracting environment (to test central auditory processing). About 2/3 of participants also volunteered to undergo a series of lumbar punctures for donation of cerebrospinal fluid (CSF), which was assayed for several biochemical markers of AD that are now understood to be present for a decade or longer before the onset of symptoms. As well, their plasma and CSF are assayed for presence of naproxen and for numerous markers of inflammatory processes (cytokines and chemokines). The central hypothesis was that administration of naproxen would not only suppress these inflammatory markers but would also slow or reverse the progress of change in cognition and in biomarkers of the pre-clinical stage of AD. The analysis plan followed the principle of modified Intent-to-Treat, considering outcomes for all persons who had at least one follow-up examination while on-protocol. After completion of two years of treatment, these participants are being followed for a further two years to observe whether treatment-related changes are sustained -- indicating that the treatment effects represent modification of the disease process itself, as opposed to a temporary change in brain function.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Investigations of Naproxen Treatment Effects in Pre-clinical Alzheimer's Disease (INTREPAD)
Actual Study Start Date : August 1, 2012
Actual Primary Completion Date : March 31, 2017
Actual Study Completion Date : July 15, 2017


Arm Intervention/treatment
Active Comparator: naproxen
naproxen sodium tablets 220 mg twice daily for two years
Drug: Naproxen
pale blue oval tablets
Other Name: Naprosyn, Anaprox, Aleve

Placebo Comparator: placebo
tablets identical in appearance to naproxen tablets twice daily for two years
Drug: Placebo
pale blue oval tablets with no active ingredients, identical in appearance to naproxen intervention
Other Name: sugar pill




Primary Outcome Measures :
  1. Trajectory of composite Alzheimer Progression Score (APS) from multiple cognitive and biomarker measures of pre-clinical Alzheimer's disease [ Time Frame: Two years for primary outcome, with intent to follow participants off-treatment for two-year observational delayed washout ]
    Summary score derived using latent trait Item Response Theory analyses, trajectory estimated from mixed effects models based on multiple individual markers observed at baseline, three months, 12 months, and 24 months following randomization


Secondary Outcome Measures :
  1. frequency and severity of treatment-emergent adverse events [ Time Frame: collected in real-time over two years following RZ ]
    classified by organ system involvement and need for treatment interruption or cessation.

  2. trajectory of cognitive abilities measured by global score on Repeatable Battery for Assessment of Neuropsychological Status [ Time Frame: observed at baseline, annually thereafter over two years following randomization (RZ), and two years further (delayed washout) ]
    global score of primary interest, although individual scale scores will be used in secondary analyses

  3. ratio of total and protein-bound naproxen concentrations as well as kinetics of drug accumulation and washout [ Time Frame: estimated at three months and annually thereafter for two years following RZ, with further two years delayed washout ]
    estimate of blood brain barrier permeability and rapidity of drug accumulation and washout in both plasma and CSF partitions

  4. biomarkers of inflammatory processes [ Time Frame: measured at three months and annually thereafter for two years following RZ, with further two years delayed washout ]
    quantitative measures of 44 different inflammatory cytokines measured in plasma, and in CSF when available

  5. CSF biomarkers of AD pathogenesis [ Time Frame: observed at baseline, after three months, and annually thereafter over two years following randomization (RZ), and two years thereafter off-treatment (delayed washout) ]
    concentrations of total tau protein, phosphorylated tau protein, Amyloid beta 1-40 and Amyloid beta 1-42, apolipoprotein E



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • good physical health including normal hemoglobin and hematocrit
  • history or documentation of AD dementia in at least one parent, or in two siblings
  • cognitive performance without diagnosable deficit such as dementia, "mild cognitive impairment"
  • must have spouse or companion able to accompany participant for clinic visits
  • six or more years of formal education
  • fluent in either English or French
  • provision of informed consent

Exclusion Criteria:

  • no current peptic ulcer disease
  • no history of prior peptic ulcer with bleed, perforation, intestinal obstruction
  • no major psychiatric disturbance
  • no regular use (4 or more doses per week) of aspirin, other non-steroidal anti-inflammatory drug (NSAID), opiate or other pain medication
  • no use, present or past, of acetylcholinesterase inhibitors or memantine
  • no regular use of vitamin E at dosage of 600 i.u.
  • no drug or alcohol dependence
  • no allergy to NSAIDs or sulfa antibiotics

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02702817


Locations
Canada, Quebec
Douglas Hospital Research Centre
Montreal, Quebec, Canada, H4H1R3
Sponsors and Collaborators
Douglas Mental Health University Institute
McGill University
Johns Hopkins University
Investigators
Principal Investigator: John C S Breitner, MD, MPH Dept of Psychiatry, McGill University Faculty of Medicine

Responsible Party: John C. S. Breitner, Director, Centre for Studies on Prevention of Alzheimer's Disease, Douglas Mental Health University Institute
ClinicalTrials.gov Identifier: NCT02702817     History of Changes
Other Study ID Numbers: INTREPAD
First Posted: March 9, 2016    Key Record Dates
Last Update Posted: August 1, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Only de-identified data will be made available, after completion of trial including delayed washout phase.
Supporting Materials: Study Protocol
Informed Consent Form (ICF)
Time Frame: Data will be available for completed trial in March, 2018. Data for delayed washout / continuation phase will be made available at biennial intervals thereafter
Access Criteria: Qualified personnel should contact principal investigator and Study Coordinator for Data Sharing Agreement form, which must be completed and reviewed prior to release of data.

Keywords provided by John C. S. Breitner, Douglas Mental Health University Institute:
Alzheimer's disease, biomarkers, cognitive decline, pre-clinical

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cognition Disorders
Cognitive Dysfunction
Dementia
Tauopathies
Naproxen
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Gout Suppressants
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action